Proton-coupled folate transporter as a biomarker of outcome to treatment for pleural mesothelioma

Pharmacogenomics. 2018 Jul 1;19(10):811-814. doi: 10.2217/pgs-2018-0071. Epub 2018 Jun 19.

Authors

Giovanna Li Petri^{1

2}, Stella Cascioferro², Barbara Parrino², Godefridus J Peters¹, Patrizia Diana², Elisa Giovannetti^{1

2

3}

Affiliations

¹ Department of Medical Oncology, VU University Medical Center, Cancer Center Amsterdam, De Boelelaan 1117, 1081HV Amsterdam, The Netherlands.
² Dipartimento di Scienze e Tecnologie Biologiche, Chimiche e Farmaceutiche, Sezione di Chimica e Tecnologie Farmaceutiche, Università degli Studi di Palermo, Via Archirafi 32, 90123 Palermo, Italy.
³ Cancer Pharmacology Lab, AIRC Start-Up Unit, University of Pisa, via Paradisa, 56100, Pisa, Italy.

PMID: 29916298
DOI: 10.2217/pgs-2018-0071

No abstract available

Keywords: PCFT; chemoresistance; mesothelioma; pemetrexed.

Publication types

Editorial
Research Support, Non-U.S. Gov't

MeSH terms

Biomarkers, Tumor / genetics
Drug Resistance, Neoplasm / genetics*
Humans
Lung Neoplasms / drug therapy*
Lung Neoplasms / genetics
Mesothelioma / drug therapy*
Mesothelioma / genetics
Mesothelioma, Malignant
Pemetrexed / therapeutic use
Pleural Neoplasms / drug therapy*
Pleural Neoplasms / genetics
Pleural Neoplasms / pathology
Proton-Coupled Folate Transporter / genetics*

Substances

Biomarkers, Tumor
Proton-Coupled Folate Transporter
Pemetrexed